Thalidomide: dual benefits in palliative medicine and oncology
- PMID: 11565189
- DOI: 10.1177/104990910101800511
Thalidomide: dual benefits in palliative medicine and oncology
Abstract
Thalidomide is an immunomodulator, anti-angiogenic agent, anti-cytokine, and anti-integrin. Alone or in combination with other drugs, thalidomide has also demonstrated anti-cachexin and anti-neoplastic properties. Anorexia and cachexia are common symptoms of advanced cancer. Since certain cytokines also promote tumor growth, we may have a class of agents with palliative and anti-tumor benefits in combination with anti-neoplastics and anti-cytokines, such as thalidomide.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources